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Abstract 
A latent MAP kinase kinase kinase activity previously detected after chromatography of PC12 cell extracts on Mono Q [(1992) FEBS Lett. 314, 
461-4651 has been identified as B-Raf by immunoblotting and immunopr~ipitation experiments and by its specific activation with B-Raf antibodies. 
B-Raf is phosphorylated after stimulation of PCI 2 cells with nerve growth factor or epidermal growth factor, but this is not accompanied by activation 
of the Mono Q-purified enzyme whether assayed in the absence or presence of GTP-Ras. 
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1. Introduction 
A protein kinase cascade has been dissected over the 
past few years which plays a critical role in mediating the 
actions of growth factors that signal via receptor protein 
tyrosine kinases. Cell stimulation by these growth factors 
leads within minutes to the activation of mitogen-acti- 
vated protein (MAP) kinase, which translocates from the 
cytosol to the nucleus and regulates transcriptional 
events that culminate in either proliferation or differenti- 
ation [l]. 
The activation of MAP kinase by growth factors is 
thought to involve first, the formation of GTP-Ras, and 
then the activation of the protein kinase c-Raf. The latter 
activates MAP kinase kinase (MAPKK) by phospho- 
rylating two serine residues [2], while MAPKK activates 
MAP kinase by phosphorylating a threonine and a tyro- 
sine residue [3]. The phosphorylation sites in MAPKK 
and MAP kinase are situated in analogous regions of the 
kinase catalytic domain, between subdomains VII and 
VIII. 
Rat phaeochromocytoma (PC1 2) cells undergo differ- 
entiation from immature chroma~n cells to a sympa- 
thetic neuron-like phenotype in response to nerve growth 
factor (NGF), and recent work strongly suggests that 
sustained activation of MAP kinase is not only required, 
but sufficient, to induce the differentiation of these cells 
[4,5]. NGF stimulation of PC12 cells activates the 
MAPKKi isoform [2] which then activates the p42 and 
p44 isoforms of MAP kinase (~42/44”“~) [6]. However, 
it is not clear which enzyme activates MAPKKl in NGF- 
stimulated PC12 cells. Almost none of the MAPKKK 
activity in PC12 cell extracts is reported to be im- 
munoprecipitated by c-Raf antibodies [7] and expression 
of a constitutively activated form of c-Raf in PC12 cells 
does not activate ~42144~“~~ [8]. Two potential candi- 
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dates for the NGF-stimulated MAPKKK are MEK ki- 
nase [9] and the protooncogene c-mos [lO,l I], both of 
which display MAPKKK activity in vitro. MEK kinase 
is a mammalian homologue of yeast protein kinases that 
lie in signailing pathways which coordinate the physio- 
logical changes that enable yeast cells to mate, and has 
been identified in a number of mammalian cells. In con- 
trast c-Mos has only been detected in germ cells where 
it plays an important role in regulating meiosis. 
We have previously detected a MAPKKK activity in 
PC12 cells after chromatography of cell lysates on Mono 
Q [12]. Unlike MAPKKl and ~42/44~“~~, this 
MAPKKK was inactive when the Mono Q fractions 
from NGF-stimulated PC12 cells were assayed immedi- 
ately after chromatography, but became active after stor- 
age for several weeks at 4°C. Since these findings were 
made before the discovery that c-Raf, MEK kinase and 
c-Mos activate MAPKK in vitro, it became important to 
identity the latent MAPKKK activity in the Mono Q 
eluate. Here we identify this enzyme as B-Raf, an isoform 
of c-Raf. 
2. Materials and methods 
2.1. Materials 
An affinity-purified antibody raised against he C-terminal sequence 
of B-Raf (ASPKTPIQAGGYGAFPVH) was a nroduct of Santa Cruz 
Biote~hn~Io~ Inc. and purchase from NBS Biologicals (North 
Mymms, Herts., UK). Antisera raised against C-terminal peptides from 
c-Raf (CTLTTSPRLPVF) and B-Raf were gifts from Dr. U. Rapp, 
NIH, Frederick, MD, USA, and antiserum raised against a C-terminal 
peptide of MEK kinase (DRPPSRELLKHPVFR) was a gift from Drs. 
C. Lange-Carter and G. Johnson, National Jewish Hospital, Denver, 
CO, USA. Sources of other materials are given elsewhere [12-14). 
N-Ras from Triton-solubilised plasma membranes of the retinal cell 
line HER313A (where N-Ras comprises 5-10% of the plasma mem- 
brane protein) was purified on Mono Q and provided by Dr. D. Alessi 
in this Unit. 
2.2. Chromatography of PC12 ceil extracts on Mono Q and assay of 
protein kinases 
Cells were cultured, stimulated [I 51, Iysed [6], and the extracts chro- 
matographed on Mono Q [12] as described previously. MAPKKK was 
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assayed by its ability to reactivate MAPKK as in [13]. This assay, which 
employs bacterially expressed MAPKKI and p42mapk, is extremely sen- 
sitive and less than 0.5% conversion of MAPKK to its activated form 
can be quantitated accurately [2]. One unit of MAPKKK activity was 
that amount which increased the activity of MAP kinase by I U in 20 
min assay [12,13]. Protein concentrations were determined by the 
method of Bradford [l6]. 
2.3. Immunoprecipitation oJ’ Ruj 
Protein A-Sepharose (100 mg) was suspended in I ml of 50 mM 
Tris-HCI, pH 7.3, 2 mM EDTA, 2 mM EGTA, 0.3 mM sodium ortho- 
vanadate, 5% (v/v) glycerol, 0.03% (w/v) Brij 35, 0.1% (v/v) 2-mercap- 
toethanol (Buffer A) and a 0.04 ml aliquot incubated for IO min at 4°C 
with Raf antibody (0.005 ml). An aliquot of activated MAPKKK from 
Mono Q (0.04 ml) was added to the Raf antibody/Protein A-Sepharose 
and the suspension incubated for 30 min at 4°C with occasional mixing. 
After centrifugation for I min at 13,000 x g, 0.065 ml of the supernatant 
was removed and the pellet washed once with 0. I ml of buffer A, once 
with buffer A containing 0.5 M NaCl and twice with 50 mM Tris-HCI, 
pH 7.5, 0.1 mM EGTA, 0.04% (by mass) Brij 35, 0.1% (by vol.) 
2-mercaptoethanol (buffer B). The pellet was resuspended in buffer B 
to a volume of 0.065 ml and aliquots of the resuspended pellet and 
supernatant were assayed for MAPKKK activity. 
Raf was immunoprecipitated from PC12 cell extracts as described 
above except that the Protein A-Sepharose was suspended in lysis 
buffer (20 mM Tris-acetate, pH 7.0, 0.27 M sucrose, I mM EDTA, 
I mM EGTA, I mM sodium orthovanadate, IO mM sodium glycero- 
phosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1% 
(w/v) Triton X-100, I mM benzamidine, 4 &ml leupeptin, 0.1% (by 
vol.) 2-mercaptoethanol) and PC12 cell extract (0.1 mg, about 0.2 ml) 
replaced MAPKKK from Mono Q. The immunoprecipitates were 
washed with lysis buffer, then with lysis buffer containing 0.5 M NaCl 
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and finally with buffer B containing the protein phosphatase inhibitor 
microcystin-LR (0. I ,uM). 
2.4. Immunoblotting with antibodies 
Aliquots of PC12 cell extracts (20 pg) or Mono Q fractions (24 ,uI) 
were denatured in SDS and subjected to SDS-PAGE on 7.5% (B-Rafl 
or 10% (c-Raf or MEK kinase) gels [l7]. The proteins were transferred 
to nitrocellulose, immunoblotted and detected as described previously 
u31. 
3. Results 
3.1. IdentiJication of the latent MAPKKK activity as 
B- Raf 
PC12 cells were chromatographed on Mono Q and, as 
reported previously [12], MAPKKK activity could not 
be detected in any of the column fractions if they were 
assayed immediately. However, immunoblotting with 
B-Raf antibodies revealed a protein of the expected mass 
(95 kDa [IS]) which co-eluted with the peak of 
MAPKKK activity that appears when the fractions are 
assayed several weeks later (Fig. 1). Furthermore, most 
of the MAPKKK activity that appeared on storage was 
precipitated by B-Raf antibodies (Fig. 2), and two differ- 
ent B-Raf antibodies raised against a C-terminal peptide 
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Fig. I. The latent MAPKKK in PC12 cells co-elutes on Mono Q with B-Raf. Cell lysates were chromatographed on Mono Q and (A) assayed for 
MAPKKK activity immediately (0), or after storing the fractions for 4 weeks at 4°C (0). The broken line shows the salt gradient. (B) 24 ~1 of the 
freshly isolated fraction were subjected to SDS-PAGE and immunoblotted with B-Raf antibodies. 
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of B-Raf activated the latent MAPKKK activity when 
added to the freshly isolated Mono Q fractions (Fig. 3). 
This activation did not occur if the antibodies were first 
preincubated with peptide immunogen (Fig. 3) indicat- 
ing that activation results from a specific interaction with 
the B-Raf antibody. In contrast, no MAPKKK activity 
was immunoprecipitated when the B-Raf antibody was 
replaced by either buffer or c-Raf antibodies (Fig. 2) 
although under identical conditions the c-Raf antibody 
immunoprecipitated most of the MAPKKK activity as- 
sociated with the solubilised plasma membranes of Ras- 
transformed retinal cells [13]. Immunoblotting of the 
Mono Q fractions with c-Raf antibodies revealed a pro- 
tein with the mass of c-Raf (70 kDa) which eluted as a 
very broad peak overlapping with B-Raf. However, the 
fractions containing the highest levels of c-Raf eluted 
later (at fractions 38 and 39) than those containing the 
latent MAPKKK activity (data not shown). Im- 
munoblotting of the same fractions with MEK kinase 
antibodies showed no immunoreactive band of the ex- 
pected mass (78 kDa [9]). 
3.2. Lack of correlation between phosphorylation and 
activation of Raf 
It has been reported that the phosphorylation of B-Raf 
increases in response to NGF or EGF, resulting in a 
small decrease in its electrophoretic mobility, which is 
maximal 5-15 min after growth factor stimulation 
[18,19]. Similar results were obtained in the present 
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Fig. 2. The MAPKKK activity from PC12 cells is immunoprecipitated 
with B-Raf antibodies. Fraction 36 from chromatography on Mono Q 
(Fig. 1) was stored for 4 weeks at 4°C to activate the latent MAPKKK 
activity and then incubated with Protein A-Sepharose alone (-), B-Raf 
antibodies coupled to Protein A-Sepharose (B-Rat) or c-Raf antibodies 
coupled to Protein A-Sepharose (C-Raf). After centrifugation of the 
Protein A-Sepharose, MAPKKK activity was measured in the im- 
munoprecipitate (P, filled bars) and supernatant (S, open bars). Activ- 
ities are expressed as a percentage of the values measured in the fraction 
before addition of antibody. The results are expressed as S.E.M. for 
three separate experiments. 
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Fig. 3. Activation of B-Raf by B-Raf antibodies. An aliquot of fraction 
36 from chromatography on Mono Q containing very little MAPKKK 
activity (Fig. 1, o) was incubated at 4°C with two different B-Raf 
antibodies raised against a C-terminal peptide of B-Raf in the absence 
(open and closed circles) or presence (open and closed triangles) of 
peptide immunogen (IOfig/ml). The closed squares show an incubation 
in which antibody and peptide immunogen were omitted. Each incuba- 
tion was assayed for MAPKKK activity at the times indicated. 
work, where the decrease in electrophoretic mobility of 
the 95 kDa band in PC12 cell lysates was detectable 
3 min after stimulation with NGF, was maximal after 
4 min and sustained for at least 30 min. After stimulation 
with EGF the mobility shift was detectable after 2 min, 
maximal after 3 min and sustained for at least 1 h (Fig. 
4A). Thus the decrease in mobility of B-Raf does not 
correlate with the activity of MAPKK-1, which is maxi- 
mally activated after stimulation with EGF for 2 min and 
then rapidly inactivated [14]. The decreased electro- 
phoretic mobility of B-Raf was retained after chroma- 
tography on Mono Q (Fig. 4B), but no MAPKKK activ- 
ity was detectable in the Mono Q fractions immediately 
after chromatography, again indicating that phosphoryl- 
ation per se is insufficient for activation. The inclusion 
of GTP (0.1 mM) and N-Ras in the assays also failed to 
activate Mono Q-purified B-Raf from NGF-stimulated 
or unstimulated PC12 cells (not shown). 
The electrophoretic mobility of c-Raf is also decreased 
when PC12 cells are stimulated with NGF or EGF [20]. 
In the present study, the mobility shift was apparent after 
stimulation for 5 min with NGF, was maximal after 15 
min and sustained for at least 30 min. In cells stimulated 
with EGF the mobility shift was only apparent after 15 
min, and sustained for at least 1 h (data not shown). Thus 
phosphorylation of c-Raf in response to EGF does not 
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Fig. 4. Phosphorylation of B-Raf in PC12 cells in response to EGF and NGF. (A) PC12 cells were stimulated with EGF (100 @ml) or NGF (50 
@ml) for the times indicated, lysed and 20 ,~g of extract subjected to SDS-PAGE and immunoblotted with B-Raf antibodies. The stronger 
immunoreactivity of the more highly phosphorylated (lower mobility) forms of B-Raf was observed in most experiments. The arrows denote the 
positions of the marker proteins phosphorylase (97 kDa) and bovine serum albumin (69 kDa). (B) PC12 cell extracts were chromatographed on Mono 
Q and fraction 36 from Fig. I was immunoblotted with B-Raf antibodies. Lanes 1 and 3, fractions from unstimulated PC12 cells; lanes 2and 4, 
fractions from PC12 cells stimulated with NGF for 15 min 
correlate with either the rate of activation or inactivation 
of MAPKKl. No MAPKKK activity was found when 
the c-Raf-containing fractions from Mono Q were as- 
sayed immediately after chromatography. Furthermore, 
no MAPKKK activity was detected when c-Raf was 
immunoprecipitated from the lysates of NGF-stimulated 
PC12 cells at any time point (data not shown). In con- 
trast, the same c-Raf antibody immunoprecipitated most 
of the MAPKKK activity from the solubilised mem- 
branes of Ras-transformed retinal cells under the same 
conditions [ 131. 
4. Discussion 
The immunoblotting and immunoprecipitation experi- 
ments (Figs. 1 and 2) and specific activation of the latent 
MAPKKK activity by the B-Raf antibody (Fig. 3) dem- 
onstrate that this enzyme is not MEK kinase, c-Mos or 
c-Raf, but an isoform of c-Raf termed B-Raf. B-Raf has 
a restricted tissue distribution and is found only in foetal 
brain and testis [20a], although its presence in PC12 cells 
has been noted before [18,19]. The C-terminal catalytic 
domain of B-Raf is 79% identical to c-Raf. The N-termi- 
nal regulatory domain is less similar, but contains the 
two conserved regions (CR1 and CR2) present in c-Raf 
[18,21], suggesting an analogous activation mechanism. 
Why B-Raf becomes activated when the Mono Q frac- 
tions are stored for several weeks at 4°C is unclear. 
N-Terminal truncation of c-Raf is known to generate a 
constitutively activated enzyme [22,23], and in several 
experiments we have observed the partial conversion of 
B-Raf during storage from the native 95 kDa form to a 
63 kDa species by i~unoblotting with the B-Raf anti- 
bodies which are raised against a C-terminal peptide 
(section 2.1). However, we have been unable to prevent 
activation with any proteinase inhibitors, and in other 
experiments a similar activation of B-Raf occurred dur- 
ing storage without significant formation of the 63 kDa 
species, suggesting that limited proteolysis may not be 
the mechanism of activation. A further possibility, con- 
sistent with effects of the antibody and of prolonged 
storage, is that activation results from the aggregation of 
B-Raf. 
The observation that antibodies raised against a 
C-terminal peptide of B-Raf activated its MAPKKK ac- 
tivity was surprising, because c-Raf is not activated by 
antibodies raised against its C-terminus. Activation of 
B-Raf was blocked by the peptide immunogen (Fig. 3) 
indicating that it results from a specific interaction be- 
tween the antibody and B-Raf, and not from proteolysis 
catalysed by a contaminating proteinase. These antibod- 
ies should therefore be useful for detecting latent forms 
of B-Raf in cell extracts. However, the present study 
suggests that they should not be used to study the activa- 
tion of B-Raf in vivo, despite the fact that they have been 
employed for this purpose previously [18,19]. When 
B-Raf was immunoprecipitated from PC12 cell extracts 
there was a high basal level of MAPKKK activity even 
in unstimulated cells, as expected from the activating 
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effect of the antibodies. This basal activity increased 
nearly 2-fold after stimulation of PC12 cells for 3-4 min 
with NGF or EGF, and remained at this elevated value 
for at least 30 min (S. Traverse, unpublished results). 
However, this activation may be artefactual if a post- 
translational modi~cation, such as phosphorylation, po- 
tentiated activation by the antibody. 
In many mammalian cells the activation of c-Raf, 
MAPKK and MAP kinase is potently inhibited by ag- 
onists that elevate the intracellular concentration of cy- 
clic AMP or by cell permeant analogues of cyclic AMP 
[2428]. Wu et al. [27] reported that the inhibition of 
c-Raf was accompanied by increased in vivo phosphoryl- 
ation of Ser-43, the residue phosphorylated by cyclic 
AMP-dependent protein kinase in vitro. They also found 
that phosphorylation of Ser-43 reduced the affinity of 
c-Raf for GTP-Ras [27], suggesting that Ser-43 phospho- 
rylation may underlie the inhibition of c-Raf activation 
by cyclic AMP. Our attempts to trigger differentiation by 
microinjecting the activating B-Raf antibodies into PC12 
cells have so far been unsuccessful (S. Traverse and A. 
Prescott, unpublished experiments). It is therefore un- 
clear whether B-Raf or another as yet unidentified Ras- 
dependent protein kinase activates MAPKKl in NGF- 
or EGF-stimulated PC12 cells [7]. However, if B-Raf was 
the relevant activity, the lack of Ser-43 in this isoform 
could explain why the activation of MAP kinase is not 
inhibited by cyclic AMP in PC12 cells [29]. 
Our finding that c-Raf is not activated by NGF in 
PC12 cells is in agreement with data reported in 171, but 
disagrees with the work of Ohmichi et al. PO]. These 
investigators did not measure c-Raf activity using the 
physiological substrate MAPKK, but by the phospho- 
rylation of c-Raf which occurred when the immunopre- 
cipitates were incubated with MgATP [30]. It is therefore 
possible that phosphorylation was not catalysed by 
c-Raf itself, but by another NGF-stimulated protein ki- 
nase present in the immunoprecipitates as a trace con- 
taminant. Because c-Raf and MAPKK are substrates for 
other kinases such as the p42 and p44 isoforms of MAP 
kinase, it is essential to measure c-Raf by its ability to 
activate MAPKK and hazardous to measure activation 
by the phosphorylation of MAPKK [7], c-Raf [30] or 
other proteins, as noted previously [2]. 
The molecular mechanism by which growth factors 
activate either c-Raf or B-Raf is unknown. Although 
GTP-Ras is known to interact with the N-terminal do- 
main of c-Raf [31-341, and c-Raf is translocated to the 
plasma membrane and activated in Ras-transformed ret- 
inal cells [13], neither we [13] nor others 1341 have been 
able to detect any direct activation of c-Raf or B-Raf by 
GTP-Ras in vitro. Furthermore, although B-Raf and 
c-Raf are phosphorylated in PC12 cells in response to 
NGF or EGF, phospho~lation does not lead to, or 
correlate with, activation. Similarly c-Raf associated 
with the plasma membranes of Ras-transformed retinal 
cells [14] is not inactivated by incubation with high con- 
centrations of a protein phosphatase ‘cocktail’, and 
c-Raf in insect St9 cells (which had been activated by co- 
expression with oncogenic Ras) is not deactivated by the 
same phosphatase treatment, although all covalently 
bound phosphate is removed (D. Alessi and P. Cohen, 
unpublished). Thus neither allosteric activation by GTP- 
Ras nor phosphorylation appear to account for the acti- 
vation of Raf by growth factors, and the role of GTP- 
Ras may be to recruit Raf to the plasma membrane 
where it is activated by an as yet unidentified mechanism. 
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